Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock Has Consensus Target Price of $291.25

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have earned an average recommendation of “Buy” from the twenty brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $290.85.

A number of research firms recently commented on JAZZ. Barclays upped their price objective on Jazz Pharmaceuticals from $270.00 to $271.00 and gave the company an “overweight” rating in a research report on Thursday, September 10th. Truist Financial increased their price target on Jazz Pharmaceuticals from $281.00 to $286.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. Weiss Ratings raised Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Robert W. Baird increased their target price on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Finally, Wells Fargo & Company increased their price target on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $211.97 on Thursday. Jazz Pharmaceuticals has a fifty-two week low of $128.80 and a fifty-two week high of $266.38. The business has a 50-day simple moving average of $237.36 and a two-hundred day simple moving average of $232.77. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The firm has a market cap of $13.76 billion, a price-to-earnings ratio of 14.62, a price-to-earnings-growth ratio of 0.22 and a beta of 0.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. Jazz Pharmaceuticals’s revenue was up 15.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($8.25) EPS. On average, analysts expect that Jazz Pharmaceuticals will post 21.59 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In related news, EVP Neena Patil sold 1,200 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $240.94, for a total value of $289,128.00. Following the completion of the sale, the executive vice president owned 47,671 shares in the company, valued at approximately $11,485,850.74. The trade was a 2.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce Cozadd sold 6,000 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $230.33, for a total value of $1,381,980.00. Following the completion of the sale, the director owned 345,875 shares of the company’s stock, valued at $79,665,388.75. This represents a 1.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 100,121 shares of company stock worth $24,855,802. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Castleark Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at about $9,214,000. SEB Asset Management AB purchased a new stake in shares of Jazz Pharmaceuticals during the first quarter valued at $8,765,000. Bank of America Corp DE increased its holdings in shares of Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after purchasing an additional 99,656 shares during the period. California Public Employees Retirement System increased its holdings in Jazz Pharmaceuticals by 10.6% in the 1st quarter. California Public Employees Retirement System now owns 124,583 shares of the specialty pharmaceutical company’s stock worth $23,552,000 after buying an additional 11,915 shares during the period. Finally, Boston Trust Walden Corp increased its stake in shares of Jazz Pharmaceuticals by 24.1% in the first quarter. Boston Trust Walden Corp now owns 488,661 shares of the specialty pharmaceutical company’s stock worth $92,381,000 after acquiring an additional 94,750 shares during the period. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.